PubMed Journals Articles About "Tredaptive Extended Release Niacin Laropiprant Placebo Tredaptive Coronary" RSS

17:08 EDT 16th October 2018 | BioPortfolio

Tredaptive Extended Release Niacin Laropiprant Placebo Tredaptive Coronary PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Tredaptive Extended Release Niacin Laropiprant Placebo Tredaptive Coronary articles that have been published worldwide.

More Information about "Tredaptive Extended Release Niacin Laropiprant Placebo Tredaptive Coronary" on BioPortfolio

We have published hundreds of Tredaptive Extended Release Niacin Laropiprant Placebo Tredaptive Coronary news stories on BioPortfolio along with dozens of Tredaptive Extended Release Niacin Laropiprant Placebo Tredaptive Coronary Clinical Trials and PubMed Articles about Tredaptive Extended Release Niacin Laropiprant Placebo Tredaptive Coronary for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Tredaptive Extended Release Niacin Laropiprant Placebo Tredaptive Coronary Companies in our database. You can also find out about relevant Tredaptive Extended Release Niacin Laropiprant Placebo Tredaptive Coronary Drugs and Medications on this site too.

Showing "Tredaptive extended release niacin laropiprant Placebo Tredaptive Coronary" PubMed Articles 1–25 of 8,500+

A Randomized, Double-Blind Study of SHP465 Mixed Amphetamine Salts Extended-Release in Adults With ADHD Using a Simulated Adult Workplace Design.

Evaluate the efficacy, duration of effect, and tolerability of SHP465 mixed amphetamine salts (MAS) extended-release versus placebo and immediate-release MAS (MAS IR) in adults with attention-deficit/hyperactivity disorder (ADHD).

Relationship between lipoprotein subfraction cholesterol and residual risk for cardiovascular outcomes: A post hoc analysis of the AIM-HIGH trial.

The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes) trial failed to demonstrate incremental clinical benefit of extended-release niacin (ERN) in 3414 statin-treated patients with established cardiovascular (CV) disease who had low baseline levels of high-density lipoprotein cholesterol (HDL-C) as compared to placebo. A previous secondary analysis suggested that ERN provided outcome benefits in ERN-treated patients with high ...

Gabapentin for the Treatment of Vulvodynia: A Randomized Controlled Trial.

To evaluate whether extended-release gabapentin is more effective than placebo among women with vulvodynia.

Extended release versus immediate release tacrolimus in kidney transplant recipients: a systematic review and meta-analysis.

To compare the estimated glomerular filtration rate (eGFR) at 12 months together with other outcomes among adult kidney transplant recipients (KTRs) who received extended release, once daily tacrolimus (ER-Tac) compared to those who received the immediate release, twice daily tacrolimus (IR-Tac) administration.

Extended release bupivacaine formulations for postoperative analgesia: an update.

New formulations of local anesthetics with sustained release and longer duration of action are being developed to improve patient outcomes following surgery. This review summarizes the efficacy and safety of the three most recently developed extended-release formulations of the local anesthetic, bupivacaine.

Niacin deficiency modulates genes involved in cancer: Are smokers at higher risk?

The role of niacin's metabolite, nicotinamide adenine dinucleotide (NAD), in DNA repair via base-excision repair pathway is well documented. We evaluated if niacin deficiency results in genetic instability in normal human fetal lung fibroblasts (MRC-5), and further, does it leads to enhanced accumulation of cigarette smoke-induced genetic damage? MRC-5 cells were grown discretely in niacin-proficient/deficient media, and exposed to nicotine-derived nitrosamine ketone (NNK, a cigarette smoke carcinogen). Nia...

Niacin action in the atherogenic mixed dyslipidemia of metabolic syndrome: Insights from metabolic biomarker profiling and network analysis.

Niacin as an adjunct to statin treatment to reduce cardiovascular risk is questioned.


The aim of this study was to compare the pharmacokinetic profile, tolerability, and safety of a novel once-daily extended-release formulation of tacrolimus (LCPT) with that of once-daily prolonged-release tacrolimus (ODT) in stable adult lung transplant (LT) recipients.

Niacin and Selenium Attenuate Brain Injury After Cardiac Arrest in Rats by Up-Regulating DJ-1-Akt Signaling.

To determine neuroprotective effects and mechanism of the combination therapy of niacin and selenium in cardiac arrest rats.

Effects of a Single Intra-Articular Injection of a Microsphere Formulation of Triamcinolone Acetonide on Knee Osteoarthritis Pain: A Double-Blinded, Randomized, Placebo-Controlled, Multinational Study.

Intra-articular corticosteroids relieve osteoarthritis pain, but rapid systemic absorption limits efficacy. FX006, a novel, microsphere-based, extended-release triamcinolone acetonide (TA) formulation, prolongs TA joint residence and reduces systemic exposure compared with standard TA crystalline suspension (TAcs). We assessed symptomatic benefits and safety of FX006 compared with saline-solution placebo and TAcs.

Neurobiology of placebo effect in Parkinson's disease: What we have learned and where we are going.

The placebo effect is a phenomenon produced when an inert substance administered like a regular treatment improves the clinical outcome. Parkinson's disease (PD) is one of the main clinical disorders for which the placebo response rates are high. The first evidence of the neurobiological mechanisms underlying the placebo effect in PD stems from 2001, when de la Fuente-Fernandez and colleagues demonstrated that a placebo injection led to the release of dopamine in the striatal nuclei of PD measured with posi...

Extended-release morphine for chronic breathlessness in pulmonary arterial hypertension - a randomised, double-blind, placebo-controlled, crossover study.

Pulmonary arterial hypertension (PAH) affects people of all ages and is associated with poor prognosis. Chronic breathlessness affects almost all people with PAH.

Effect of ACE-inhibition on coronary microvascular function and symptoms in normotensive women with microvascular angina: A randomized placebo-controlled trial.

Studies have suggested a beneficial effect of angiotensin-converting enzyme (ACE) inhibition. To explore whether the ACE inhibitor ramipril has a direct effect on the microvasculature beyond the blood pressure (BP) lowering effect, we investigated whether ramipril improved coronary microvascular function in normotensive women with coronary microvascular dysfunction (CMD).

Modulation of Hepatic Gene Expression Profiles by Vitamins B1, B2 and niacin Supplementation in Mice Exposed to Acute Hypoxia.

This study was aimed to observe the effects of vitamins B1, B2 and niacin supplementation on hepatic gene expression profiles in mice exposed to acute hypoxia. Thirty mice were randomly divided into normal, acute hypoxia, and acute hypoxia plus vitamins B1, B2 and niacin supplementation groups and fed corresponding diets for two weeks and then exposed to a simulated altitude of 6000 meters for 8 hours. Hepatic gene expression profiles were analyzed using a microarray technique. Several biochemical markers w...

Amantadine Extended-Release (GOCOVRI): A Review in Levodopa-Induced Dyskinesia in Parkinson's Disease.

Amantadine extended-release (ER) capsules (GOCOVRI) are approved in the USA for the treatment of dyskinesia in patients with Parkinson's disease (PD) receiving levodopa-based therapy, with or without concomitant dopaminergic medications. With a recommended dosage of 274 mg once daily at bedtime, this new formulation of amantadine allows a more gradual time to peak plasma amantadine concentration and higher drug concentrations in the morning and throughout the day, the time period when levodopa-induced dysk...

Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia.

Preclinical and clinical studies suggest amantadine immediate-release (IR) may reduce dyskinesia in Parkinson's disease (PD), although higher doses are associated with increased CNS adverse events (AEs). ADS-5102 is an extended release amantadine capsule formulation, designed for once-daily dosing at bedtime (qhs) to provide high concentrations upon waking and throughout the day, with lower concentrations in the evening. The pharmacokinetics (PK) of ADS-5102 were assessed in two phase I studies in healthy...

Yeast culture increased plasma niacin concentration, evaporative heat loss, and feed efficiency of dairy cows in a hot environment.

The supplementation of dairy cows with yeast culture may increase diet digestibility, plasma niacin concentration, heat dissipation, and lactation performance. Our objective was to evaluate the response of Holstein cows in late lactation (234 ± 131 d in milk) to dead yeast culture (YC, 15 g/d, Factor SC, GRASP, Saccharomyces cerevisiae) during Brazilian summer (temperature-humidity index >68 for 92.2% of the time). Thirty-two cows were individually fed a standard total mixed ration for 14 d and control (CT...

Correlation Between Extended Leukocyte Differential Count and Coronary Artery Disease.

Leukocyte count is closely associated with the risk of coronary artery disease (CAD). Levels of leukocyte subpopulations in CAD patients, however, remain largely unknown.

Perivascular adipose tissue: a new possible tissue augmenting coronary vasodilatation in response to acute hypoxia.

In the present volume of Acta Physiologica, Donovan et al. propose that release of hydrogen sulfide (H S) from perivascular adipose tissue (PVAT) augments hypoxic vasorelaxation in large coronary arteries. There is a direct relationship between myocardial oxygen (O ) consumption and coronary blood flow during a variety of interventions. This article is protected by copyright. All rights reserved.

Fabrication and statistical optimization of starch-κ-carrageenan cross-linked hydrogel composite for extended release pellets of zaltoprofen.

The current study was aimed to develop extended release (ER) pellets formulations containing zaltoprofen as a model drug and cross-linked starch-κ-carrageenan (Sκ-C) hydrogel composite as a binder and extended release polymer. The Sκ-C cross-linked hydrogel composites were prepared using a 3 full factorial design approach and characterized by FTIR, DSC, XRD and SEM analysis. The matrix pellets were prepared by extrusion-spheronization technique and characterized production yield, FTIR, DSC, XRPD, SEM, op...

Cardiac shock wave therapy for refractory angina: angiogenesis, placebo effects, and randomized trial designs.

Myocardial Infarction Subtypes in Patients With Type 2 Diabetes Mellitus and the Effect of Liraglutide Therapy (from the LEADER Trial).

Diabetes mellitus (DM) is a known risk factor for myocardial infarction (MI); however, data regarding MI subtypes in people with diabetes are limited. In the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial (n = 9,340), liraglutide significantly reduced the risk of major adverse cardiovascular (CV) events (composite of CV death, nonfatal MI, or nonfatal stroke) versus placebo in patients with type 2 DM and high CV risk. Liraglutide also reduced risk ...

Historical Milestones in the Management of Stable Coronary Artery Disease over the Last Half Century.

Coronary revascularization for coronary artery disease dates to the introduction of coronary bypass surgery by Favaloro in 1967 and coronary angioplasty by Gruentzig in 1977 and first published in 1968 and 1978, respectively. There have been many technical improvements over the ensuing 5 decades, studied in clinical trials. This paper reviews the history of coronary revascularization, the development of optimal medical therapy, and points the way to the future of stable coronary artery disease management.

Placebo analgesia persists during sleep: An experimental study.

Although placebo analgesia is a well-recognized phenomenon with important clinical implications, the possibility that placebo effects occur during sleep has received little attention. This experimental study examined whether responsiveness to acute heat pain stimuli applied during sleep could be reduced following a placebo conditioning procedure administered before sleep. Healthy individuals (n = 9) underwent polysomnographic recordings for one habituation night followed by one placebo analgesia night a...

Nitroglycerin application and coronary arteriogenesis.

In the presence of a coronary occlusion, pre-existing small collateral vessels (arterioles) develop into much larger arteries (biological bypasses) that have the potential to allow a certain level of perfusion distal to the blockage. Termed arteriogenesis, this phenomenon proceeds via a complex combination of events, with nitric oxide (NO) playing an essential role. The aim of this study was to investigate the effects of supplemental administration of NO donors, i.e., short-acting nitroglycerin (NTG) or slo...

Quick Search